Compare COCH & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COCH | MYO |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Blank Checks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 44.8M |
| IPO Year | N/A | 2017 |
| Metric | COCH | MYO |
|---|---|---|
| Price | $0.67 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $7.67 |
| AVG Volume (30 Days) | 283.8K | ★ 387.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | $1.58 | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.36 | $0.61 |
| 52 Week High | $1.89 | $1.84 |
| Indicator | COCH | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 65.39 |
| Support Level | $0.63 | $0.92 |
| Resistance Level | $0.74 | N/A |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 34.67 | 80.23 |
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.